Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Navidea Biopharmaceuticals
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.
Eligibility Criteria
Treatment Details
2Treatment groups
Experimental Treatment
Group I: Subjects Free of Inflammatory DiseaseExperimental Treatment1 Intervention
The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
Group II: Healthy Controls and RA Subjects on Stable TherapyExperimental Treatment1 Intervention
The second arm is comprised of \[1\] disease-free HCs and \[2\] clinically diagnosed RA subjects on stable treatment.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Altoona Center for Clinical ResearchDuncansville, PA
Sun Research InstituteSan Antonio, TX
San Marcus Research ClinicMiami Lakes, FL
Innovation Medical Research CenterPalmetto Bay, FL
More Trial Locations
Loading ...
Who is running the clinical trial?
Navidea BiopharmaceuticalsLead Sponsor